

Please type a plus sign (+) inside this box → ☐

PTO/SB/05 (4/98)
Approved for use through 09/30/2000. OMB 0651-0032
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

UTILITY PATENT APPLICATION TRANSMITTAL

(Only for new nonprovisional applications under 37 C.F.R. § 1.53(b))

Attorney Docket No.	
First Inventor or Application Identifier	Anzellini F.
Title	Medical Dr. Cardiologist
Express Mail Label No.	

APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents.

- ☒ * Fee Transmittal Form (e.g., PTO/SB/17)
(Submit an original and a duplicate for fee processing)
- ☒ Specification [Total Pages **32**]
(preferred arrangement set forth below)
 - Descriptive title of the invention
 - Cross References to Related Applications
 - Statement Regarding Fed sponsored R & D
 - Reference to Microfiche Appendix
 - Background of the invention
 - Brief Summary of the invention
 - Brief Description of the Drawings (if filed)
 - Detailed Description
 - Claim(s)
 - Abstract of the Disclosure
- ☒ Drawing(s) (35 U.S.C. 113) [Total Sheets **8**]
- Oath or Declaration [Total Pages **40**]
 - ☒ Newly executed (original or copy)
 - ☐ Copy from a prior application (37 C.F.R. § 1.63(d))
(for continuation/divisional with Box 16 completed)
 - ☐ DELETION OF INVENTOR(S)
Signed statement attached deleting inventor(s) named in the prior application, see 37 C.F.R. §§ 1.63(d)(2) and 1.33(b).

* NOTE FOR ITEMS 1 & 13: IN ORDER TO BE ENTITLED TO PAY SMALL ENTITY FEES, A SMALL ENTITY STATEMENT IS REQUIRED (37 C.F.R. § 1.27), EXCEPT IF ONE FILED IN A PRIOR APPLICATION IS RELIED UPON (37 C.F.R. § 1.28).

ADDRESS TO: Assistant Commissioner for Patents
Box Patent Application
Washington, DC 20231

- ☐ Microfiche Computer Program (Appendix)
- Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)
 - ☐ Computer Readable Copy
 - ☐ Paper Copy (identical to computer copy)
 - ☐ Statement verifying identity of above copies

ACCOMPANYING APPLICATION PARTS

- ☐ Assignment Papers (cover sheet & document(s))
- ☐ 37 C.F.R. § 3.73(b) Statement of Power of Attorney (when there is an assignee)
- ☐ English Translation Document (if applicable)
- ☒ Information Disclosure Statement (IDS)/PTO-1449 [Copies of IDS Citations]
- ☐ Preliminary Amendment
- ☒ Return Receipt Postcard (MPEP 503)
(Should be specifically itemized)
- ☒ * Small Entity Statement(s) [Statement filed in prior application, Status still proper and desired (PTO/SB/09-12)]
- ☐ Certified Copy of Priority Document(s) (if foreign priority is claimed)
- ☐ Other: _____

16. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment:

☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No: _____

Prior application information: Examiner _____ Group / Art Unit: _____

For CONTINUATION or DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 4b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

17. CORRESPONDENCE ADDRESS

☐ Customer Number or Bar Code Label

(Insert Customer No. or Attach bar code label here)

or ☒ Correspondence address below

Name	Fernando Anzellini				
Address	Calle 83 No 19-36 (of.704)				
City	Bogota	State		Zip Code	
Country	Colombia	Telephone	57-1-6160959	Fax	57-1-61609091

Name (Print/Type)		Registration No. (Attorney/Agent)	
Signature		Date	Sept 3 1999

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**STATEMENT CLAIMING SMALL ENTITY STATUS
(37 CFR 1.9(f) & 1.27(b))--INDEPENDENT INVENTOR**

Docket Number (Optional)

Applicant, Patentee, or Identifier: Fernando Anzellini

Application or Patent No.: _____

Filed or Issued: _____

Title: Medical Dr. (Cardiologist)

As a below named inventor, I hereby state that I qualify as an independent inventor as defined in 37 CFR 1.9(c) for purposes of paying reduced fees to the Patent and Trademark Office described in:

- ☒ the specification filed herewith with title as listed above.
☐ the application identified above.
☐ the patent identified above.

I have not assigned, granted, conveyed, or licensed, and am under no obligation under contract or law to assign, grant, convey, or license, any rights in the invention to any person who would not qualify as an independent inventor under 37 CFR 1.9(c) if that person had made the invention, or to any concern which would not qualify as a small business concern under 37 CFR 1.9(d) or a nonprofit organization under 37 CFR 1.9(e).

Each person, concern, or organization to which I have assigned, granted, conveyed, or licensed or am under an obligation under contract or law to assign, grant, convey, or license any rights in the invention is listed below:

- ☒ No such person, concern, or organization exists.
☐ Each such person, concern, or organization is listed below.

Separate statements are required from each named person, concern, or organization having rights to the invention stating their status as small entities. (37 CFR 1.27)

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28(b))

Fernando Anzellini

Arturo Sesana

Mario Gongora

NAME OF INVENTOR

NAME OF INVENTOR

NAME OF INVENTOR

Signature of inventor

Signature of inventor

Signature of inventor

Sept 3 1999

Sept 3 1999

Sept 3 1999

Date

Date

Date

1.

Patent Application of

Fernando Anzellini Fajardo

Arturo Sesana

Mario Gongora

**TITLE :Early warning apparatus for Acute Myocardial Infarction in the first six
hours of pain. (CARDIOST)**

CROSS- REFERENCE TO RELATED APPLICATIONS

Not applicable

BACKGROUND-FIELD OF INVENTION

The CARDIOST relates to a unit capable of informing a user with no medical background when he/she is suffering an Acute Myocardial Infarction in the first 4 to 6 hours of chest pain.

BACKGROUND-DESCRIPTION OF PRIOR ART

There are many electrocardiographic (ECG) measuring apparatuses. Many of them can measure the ST segment (and other parts of the electrocardiogram wave) but are not meant to alert as to the possibility of an Acute Myocardial Infarction, and they have to be used by qualified medical personnel.

The portable electrocardiographic monitoring devices are used for long-term collection of ST segment data and many other measurements. Some of these devices perform simple real-time analyses limited to ischemia period detection and recording. These devices are used over a long period of time (usually 24 hour periods) for passive recording and analysis. After this period the data has to be downloaded

from the device and analyzed by qualified medical personnel for the final opinion. These devices have to be carried by the patient for the complete period of data recording, which makes them uncomfortable no matter how small they are.

Patent No. 5,433,209 issued to Gallant et al. July 1995 fully describes an ambulatory recording device that measures the ST segment for further analysis by a physician, which is incorporated herein as reference entitled "recorder unit for ambulatory ECG monitoring system". This unit does not measure the ST segment in immediate analysis and therefore is not able to diagnose Acute Myocardial Infarction in real time at the moment of real pain when it is necessary for the patient to seek medical advice for early thrombolysis. This Patent is intended to analyze all the waves of the electrocardiogram other than the ST segment and the baseline. The mentioned Patent also includes accumulation and recording of "minute-by-minute", "hour-by hour" and "end of period" summary information that is not used in acute settings.

Patent No 5,713,367 issued to Arnold et al. Feb. 1998 for measuring and assessing cardiac electrical stability and the alternans pattern of cycle-to cycle variability in physiologic waveforms does not measure S-T segment but alternans of the QRS wave to assess the risk of ventricular arrhythmias, as does the signal average electrocardiogram by averaging many repetitive waveforms, and much of the existing hardware can be used for both systems. Neither of these systems is intended for acute ischemia diagnosis .

Patent No. 5,584,868 issued to Salo et al. Dec. 1996 is a cardiac stimulating apparatus and method for heart failure therapy that includes a dual chamber pacemaker on an invasive basis that is not intended with our invention, and a cardiac defibrillator for reducing cardiac lethal arrhythmia and sudden death by the means of electric shock provided by the defibrillator.

Patent No. 3,868,567 issued to Ekstrom et al. Feb. 1975 is related to the PQ level of the same waveform employing delta modulation and demodulation for processing information overlapping the ST segment with a predetermined electrocardiographic form and making an average between two segments of waveforms, but does not trigger any visual or audible alarm intended for early diagnosis of Acute Myocardial Infarction.

Patent No. 3,991,747 issued to Stanly et al. Nov. 1976 is a electrocardiographic device for telephonic or radio transmission to an analyzing facility, converting the signals to audio output, not intended to be analyzed by the patient himself, and displays the full extent of the 12 EKG leads. The device described in this Patent does not have an audio or visual alarm.

Patent No. 4,318,412 issued to Stanly et al. March 1982 is intended to provide and optimize the placement of cardiac electrodes and to improve the signal processing but is not intended for early diagnosis of Acute Myocardial Infarction nor does it examine the ST segment. This arrangement obtains 90% of the information from a 12-lead electrocardiogram .

Patent No. 4,546,776 issued to Bellin et al. Oct. 1985, which analyzes PQ and ST portions of an electrocardiogram waveform and establishes a normal or standard ST ratio deviation between the difference of ST and PQ level, has an actuating alarm if heartbeats exceeds or is lower than a predetermined rate. When the ST segment triggers the alarm it is made on the basis of a standard ST deviation value in this Patent. Also it is emphasized that the ST segment is measured continuously. This invention is intended to be used in exercise conditions such as jogging. While this Patent indicates that a depression of approximately 100 microvolts is usually “normal”, we consider that this degree of depression in acute pain is enough to trigger an alarm of “medium risk” (yellow light). In this Patent the alarm is intended in part to warn the user to “cease vigorous activity” and does not seek an immediate use of thrombolysis. The PQ level is used and compared to the ST level instead of comparing to the baseline, which is universal in the electronic signal of any electrocardiogram.

Patent No. 4,679,144 issued to Cox et al Jul. 1987 includes a programmable apparatus carried by an ambulatory patient for performing continuous real time analysis of EKG information by permanently carrying the device and analyzing the TP segment against the ST segment. Emphasis is made on the slope of the current EKG amplitude minus previous EKG amplitude, so only the patient intended to use the apparatus can take advantage of the diagnosis instead of any other person where the baseline is used as reference.

Patent No. 4,930,075 issued to Kortas et al. May 1990 focuses only on the quantification of the ST depression, slope and length of the ST segment and is a software implemented method for analysis, but is not intended as a device for self diagnosis of acute ischemia. It studies principally a precise mathematical relationship between the values of the S-T segment.

Patent No. 4,957,115 issued to Selker et al. Sept. 1990 is intended as a device for determining the probability of death in cardiovascular patients and a method for assessing mortality risk at a health care facility. It is a computer adapted to receive the output and calculate a numerical value representing the output-based probability.

Patent No. 5,003,983 issued to Dingwall et al. April 1991 is intended to provide an improved cardiac monitoring system to measure the deviation of the S-T segment and pulse rate in a package that can be easily and unobtrusively attached to a patient, for example, during an exercise routine, or long term monitoring.

Patent No. 5,058,597 by Onoda et al. Oct. 1991 has an R wave detector determining the heart rate and the ST value of the ECG signal over a long period of time while being carried by a subject who presses an event switch on feeling a subjective symptom (includes pain) but, instead of triggering an alarm after

analyzing the ST segment, the electrocardiographic signal is written to another storage which is assigned to waveforms. The electrocardiograph records a minimum necessary amount of information for screening, i.e. the heart rates, ST values, and waveforms of electrocardiographic signal associated with subjective symptoms.

Patent No. 5,181,519 issued to Bible et al. Jan.1993 detects the ST segment but is not intended to trigger an alarm when any shift of the segment is detected, the associated signal is then stored while the monitoring unit continues to search for further measured ST deviations exceeding the threshold ST deviation and subsequently the recorded signals and associated data can be displayed by transmitting it from the monitoring unit to a remote display unit via a data transmission unit.

Patent No. 5,226,424 issued to Bible et al. Jul.1993 determines the ST segment characteristics useful in diagnosing myocardial ischemia, but operates continuously and focuses on a low energy consumptive portable heart monitor which derives from the fact that processing of the analog data requires considerably less energy than does processing the digital data continuously in normal operating mode. and is not intended to trigger an alarm when Acute Myocardial Infarction occurs.

Patent No. 5,456,261 issued to Luczyk et al. Oct. 1995 analyzes a plurality of the electrocardiographic signals for determining the existence of rhythm abnormalities, infarction, hypertrophy and repolarization abnormalities, and is not a solution for early and immediate diagnosis of acute ischemia and infarction self made by the patient himself.

Patent No 5,464,020 issued to Lerner et al. Nov. 1995 is intended for the diagnosis of subacute cardiac dysfunction and not for acute ischemia.

Patent No 5,718,233 issued to Selker et al. Feb. 1998 is only for continuous monitoring in a patient who has a cardiovascular disease and is a predictive instrument for computing a patient's probability of a serious cardiac condition, it is not intended to be used in acute settings and pain.

Patent No 5,792,066 issued to Kwong et al. Aug. 1998 is intended to be used in patients who have underlying heart conditions which mimic Acute Myocardial Infarction, and remedies a deficiency in the prior art methods and systems for this diagnosis by detecting a wave amplitude ratio (e.g. the ST complex amplitude divided by the S wave component amplitude at some specified instant in time). It calculates and compares to predetermined criteria and on the basis of this comparison it indicates whether Acute Myocardial Infarction is occurring. Thus it is unique in diagnosis only for the patient who

uses the device but cannot be used by any other person if pain is present because it compares ST amplitude divided by S wave component of the same patient against a predetermined criteria rather than against the baseline which is universal for any electrocardiogram, and does not provide any audible or visual alarm triggered by the ST segment shift.

Patent No 5,813,979 issued to Wolfer et al. Sept. 1998 describes storable conductors for expeditiously facilitating the manual administration, storage and dispensing of individual electrode leads to a patient in emergency situations when setup and operation is difficult, and is not intended for self-diagnosis of Acute Myocardial Infarction by the patient in acute pain.

Patent No 5,876,351 issued to Rohde et al. Mar. 1999, in which a medical component is removable and connected to the platform, has specialized circuitry specific to a predetermined medical function. It is used for obtaining ECG in a cost-effectiveness basis designed primarily for playing video games.

Patent No 5,562,711 issued to Yerich et. Al. Oct. 1996 is provided with circuitry for sensing a plurality of physiologic parameters intended to be indicative of increased cardiac output and is a body implantable cardiac pacemaker.

Patent No 5,662,688 issued to Haefner et al. Sept. 1997 is a system and method that automatically controls a gain of a cardioverter/defibrillator and delivers shock pulses in response thereto.. A detection

circuit detects depolarizations and provides a signal representing a cardiac event indicative only on depolarization.

Patent No 5,683,444 issued to Huntley et al. No. 1977 is an implantable assembly for defibrillation in the form of flexible electrode that delivers energy more efficiently to body tissues than conventional defibrillation electrodes.

Patent No 5,462,504 issued to Trulaske et al. Oct. 1995 is a method and apparatus for maintaining the heart rate of a user of a fitness apparatus and is intended to be incorporated into a treadmill.

Patent No 4,073,011 issued to Cherry et al. Feb 1978 is an electrocardiographic computer with a multi-speed magnetic tape scanning device for processing and observing in a relatively short interval of time large quantities of ECG signals from two pairs of ECG leads.

Patent No 4,006,737 issued to Cherry Feb 1977 is a device for processing and observing in a relatively short interval of time large quantities of ECG signals from two pair of ECG leads. The trend information is heart rate and ST segment level to provide a scanning of an entire 24 hour tape in 12 minutes.

Patent No 4,299,233 issued to Lamelson Nov. 1981 is a device on which a human body may lie or

recline for body vibrations such as heart pulses, respiration or body tremors. A transducer is operatively coupled to the liquid.

Patent No 4,362,164 issued to Little et al. Dec 1982 is a audio transducer that has a body which on one side mounts an electrode carrying chest belt. A microphone and a rotor assembly are mounted in a cavity in the body, and communicates through passages in the rotor assembly with the electrode carrying chest bell when the rotor assembly is in a first position and with the conventional chest bell when the rotor assembly is rotated to a second position.

Patent No 4,628,939 issued to Little et al. Dec. 1986 is a method and associated means for producing simultaneous electrical representations of the electrical and acoustic activity of the heart in which a pickup device and associated circuits produce a full wave rectified symmetrical heart sound signal annotated by pulses developed from the QRS wave of the electrocardiogram signal.

Patent No 4,838,275 issued to Lee Jun 1989 is an apparatus that includes special furniture on which the patient lies an sits, and embedded in which are devices that automatically sense multiple parameters related to the patient's health. The patient cooperates only passively and transmits these signals from the patient's home to a central surveillance and control office.

Patent No 5,042,497 issued to Shapland Aug 1991 is a system for predicting and preventing cardiac arrhythmia for the use in combination with an implanted arrhythmia treatment device. The preventative actions include overdrive pacing of the heart.

Patent No 5,135,004 issued to Adams et al. Aug 1992 is an implantable device that assists in the diagnosis of myocardial ischemia of a human heart and includes a plurality of electrodes and a like plurality of sense amplifiers for generating an electrogram for each of the electrodes. A digital to analog converter reads the voltage magnitudes of the electrocardiogram ST segments which are then stored in a memory. An implantable receiver/transmitter is arranged to transmit the magnitudes of the electrocardiogram ST segments to a nonimplanted external receiver.

Patent No 5,181,519 issued to Bible Jan 1993 is a portable apparatus and method for monitoring heart muscle electrical activity includes a plurality of electrical contacts that transmits the signals to the monitoring unit. Whenever a series of ST segments exhibit an ST deviation from the reference axis which exceeds a predetermined threshold deviation, the monitoring unit records data relating thereto which is used for diagnosis of myocardial ischemia.

Patent No 5,235,976 issued to Spinelli Aug 1993 is a cardiac rhythm management device in which the rate controlling parameter of a rate adaptive pacemaker is the heart's total active time used as an indication of hemodynamic instability for triggering a defibrillation

Patent No 5,685,303 issue to Rollman et al. Nov. 1977 is a belt like strip for recording electrocardiograms insuring proper placement on the patient's chest or precordium during usage.

Foreigns Patents No GB 2061521A issued to DavisHowell Jenkins May 1981 measures the individual's susceptibility to cardiovascular disorder with a visual indicator displaying one of a series of indications and enabling answers to be entered. Patent SU 1570-709-A issued to Leca June 1990 is a human's heart action monitor that measures heart contraction frequency and ST segment shift. Patent 2 315 064 issued to Burchard Mar 1973 measures ST fall arrhythmia's with continuously selectable prematurity index and intervals, tachy- and bradycardias, in continuously adjustable intervals and/or frequency regions. Patent DD 281 957 A5 issued to Krinke Aug 1990 determines the time occurrence of R-blips, QRS complexes and P-waves and allows a complex description of irregularity as well as formulation. Patent DE 3633-983 A issued to Wasser Oct 1986 measures variations in voltage characteristics and provides a high degree of freedom movement; different output signals are provided in dependence on the variation rate. Patent 5-64632 (A) issued to Takashi Suzuki Mar 1993 enables quick finding of calculating conditions ensuring a better ST deviation trend graph. Patent 405176906 (A) issued to Mutsuo Kaneko Jul 1993 measures a peak value of ST segment at an arbitrary measuring point displaying successively generated ST trend graphs, so that many derived electrocardiogram waveforms can be recognized easily.

SUMMARY

The object of the CARDIOST is to provide a device capable of instantaneous electrocardiographic measurement and real-time analysis of the ST segment in order to detect an Acute Myocardial Infarction so that a user can differentiate it from other types of chest pain through code color-audible alarms and seek immediate medical attention before 4-6 hours for proper treatment to be installed. This device can be used by the owner himself or by any other nearby person because it uses as reference for the ST segment shift the baseline of the electrocardiogram which is universal for everyone.

OBJECTS AND AN ADVANTAGES

Accordingly, the main objects and advantages of our CARDIOST are that it allows for a real-time diagnosis made by the patient himself at the time of acute pain and thus enables him/her to seek immediate medical attention for precordial pain. Failure to consult immediately is one of the leading causes of mortality and morbidity in Acute Myocardial Infarction (AMI) which in itself is a leading cause of mortality in humans. Not to consult within 4-6 hours of acute pain is one of the major public health problems in the world, as supported by thousands of

papers and studies all over the world. Other devices which make automatic diagnoses of Acute Myocardial Infarction need to be read and interpreted by a physician who most of the time is not available when the patient really needs the diagnosis.

Another object of the CARDIOST is to provide a portable apparatus, small in size, of light weight, and with a low power consumption, which can measure electrocardiographic data and analyze same digitally and instantaneously.

It is a further object of our CARDIOST to provide a device that measures either a positive or negative ST segment shift from the baseline, providing the user within seconds of the measurement with a warning of a possible Acute Myocardial Infarction.

It is yet another object of CARDIOST to provide a device capable of instantaneous electrocardiographic measurement that can be used easily by any person, preferably the patient himself, even if such person is under the stress of thinking that he/she is having a heart attack.

Finally, the CARDIOST is designed to help a patient to distinguish between the common symptoms of chest pain and those of Acute Myocardial Infarction, which is usually very confusing and subjective.

These and other purposes of the CARDIOST are achieved by means of the embodiment of a portable electrocardiographic measuring and analyzing unit, preferably a small, low-power electronic unit. The electronic unit consists of an electrocardiographic signal amplifier connected to the patient via a five-lead electric connection, a positive electrode at the rear of the device, and a neutral electrode also at the rear part of the device, both of which make contact with the precordial skin of the patient, and three more electrodes placed in the left armpit, right armpit and lower abdominal wall (hypogastrium). The device then immediately measures the signal.

The signal from the electrocardiographic amplifier is digitized by an ADC (Analog to Digital Converter) unit and recorded for a few seconds by an electronic analysis unit consisting preferably of an electronic microcontroller.

The electronic analysis unit extracts the ST segments of the electrocardiographic signal and measures its elevation or depression **in relation to the baseline**. The ST segment of a typical healthy heart is a straight line of zero slope on or near a horizontal reference axis; if there is a significant deviation from the reference axis, the heart muscle signal is termed anomalous which is indicative of an unhealthy heart muscle. It is of primary importance for the electrocardiogram not to be analyzed against a predetermined and stored reference or normal value for the patient but against the baseline. so

it can be used not only by the owner himself of the device and thus it can help anybody around him to diagnose acute ischemia if needed, considering that the baseline is a universal electronic signal of any human electrocardiogram. Depending on the result of the ST analysis in a few ECG signal periods, the electronic analysis unit turns on an alarm if the analysis indicates the possible presence of an Acute Myocardial Infarction.

There is great public health concern as to an early diagnosis of Acute Myocardial Infarction, given that a large proportion of patients fails to seek medical attention within the first 4 to 6 hours of the onset of chest pain. If proper medical diagnosis and care are provided within this critical period (of the initial 4 to 6 hours), many lives can be saved with the use of thrombolysis drugs or any other treatment that can be furnished upon further investigation. It is for these cases that the CARDIOST is intended.

Further objects and advantages of our invention will become apparent upon consideration of the drawings and ensuing description.

DESCRIPTION OF DRAWINGS

In the drawings, closely related figures have the same number but different alphabetic suffixes.

Figs. 1A and 1B show how the CARDIOST portable electrocardiographic device is attached with a negative wire to the right armpit, with a positive/negative wire to the left armpit, and a positive wire to the lower part of the abdomen the hypogastrium. Behind the CARDIOST there is a positive and negative electrode placed in a V4 position at the 6th to 8th intercostal space with mid-clavicular line. These electrodes may be placed against the skin without any gel or conductive substance.

Fig. 1 C shows a CARDIOST device from the rear with the neutral electrode and precordial positive electrode that are intended to be placed in the precordial area V 4.

Fig. 1 D shows the rear of the device and the battery compartment.

Fig. 2 A shows a normal electrocardiogram with the baseline and normal waves named P, QRS, T and electrocardiographic segments PR, ST and QT. The J point is determined as the point where the QRS reaches the baseline.

Figs 2B 2C and 2D show a shift of ST segment below the baseline which triggers a green alarm between 0-1 millimeters or 0-100 microvolts , yellow alarm between 1-2 millimeters or 100-200 microvolts and red alarm between 2 millimeters or 200 microvolts or over.

Figs. 2E 2F and 2G show a shift of the ST segment above the baseline which triggers a green alarm between 0-1 millimeters or 0-100 microvolts , yellow alarm between 1-2 millimeters or 100-200 microvolts and red alarm between 2 millimeters or 200 microvolts or over.

Fig. 3A shows an internal diagram of the device with the electrodes entering an instrumentation amplifier that sends signals to the Analog to Digital Converter (ADC) reading the ECG in real time and triggering the respective alarm.

Fig 3B show the program flow diagram used inside the microcontroller. The program measures the electrocardiographic data, extracts the baseline, determine the ST segment deviation and, depending on same, turns on the alarm where the analysis indicates the possible presence of Acute Myocardial Infarction.

REFERENCE NUMBERS IN DRAWINGS

- 4 common cable
- 5 positive/negative left armpit cable
- 6 negative right armpit cable
- 7 positive abdomen cable
- 8 cardiost
- 9 ST segment
- 10 baseline
- 11 V4 positive electrode
- 12 neutral electrode
- 13 battery compartment
- 14 J point
- 15 ECG amplifier
- 16 analog to Digital Converter
- 17 microcontroller Unit
- 18 green alarm light
- 19 yellow alarm light
- 20 red alarm light
- 21 audible tone alarm
- 22 T wave

DETAILED DESCRIPTION OF THE INVENTION

As illustrated in Fig. 1 A (top view) and Fig. 1 B (end view) a device **8** is comprised of a plastic housing which has a permanently attached electrode cable extending from it, **4** , a cable has 3 electrode lead inputs located at the remote end, **5,6,7** and these leads connect to electrodes placed in contact with the patient's body to provide electrical input of his/her electrocardiographic signals. In the right armpit the electrode is negative **6**, in the left armpit the electrode is positive/negative **5** ,and in the lower portion of the abdomen, the hipogastrium, the electrode is positive **7**.

As illustrated in Fig. No 1 C, at the rear end of a device **8** a positive electrode **11** is used to be placed in the precordial area in V 4 to record one electrocardiographic signal that we think is enough for diagnosis of the anterior wall of the heart. A neutral electrode **12** is also shown.

As illustrated in Fig. 1 D, a battery compartment **13** is located within a device **8**, preferably for 1.5 volt alkaline (size AA/AAA) disposable batteries to supply power. A device **8** may be placed in a carrying case, to be used by the patient at any time at night or day, when feeling a chest pain. Since a device may be used immediately at any time, the patient will have a high probability of ensuring a timely diagnosis.

As illustrated in Fig. 2A, a normal electrocardiogram has P as the first positive wave of the electrocardiogram for auricular contraction, Q as the first negative wave of the electrocardiogram, R as the second positive wave, and S as the second negative wave, which make up the QRS complex for ventricular contraction, the ST segment **9** from the J point **14** to the beginning of T wave **22**, 80 milliseconds past this J point **14**, where ischemia factors are detected, and T wave **22** the last positive wave of the electrocardiogram which accounts for ventricular repolarization. A baseline **10** is the basic line between P, QRS and T wave **22**.

As illustrated in Fig. 2 B, this shift of the ST segment **9** can range negative from 0 to 1 millimeters (0 to 100 microvolts) to be considered as low risk (green light **18**), in Fig 2 C segment ST **9** from 1 to 2 millimeters negative (100 to 200 microvolts) to be considered as medium risk (yellow light **19**)

and in Fig 2 D segment ST 9 from 2 millimeters and over negative (200 microvolts or over) to be considered as high risk (red light 20) for Acute Myocardial Infarction of the subendocardial type.

As illustrated in Fig 2 E this shift of the ST segment 9 can range positive from 0 to 1 millimeters (0 to 100 microvolts) to be considered as low risk (green light 18) , in Fig 2 F segment ST 9 from 1 to 2 millimeters positive (100 to 200 microvolts) to be considered as medium risk (yellow light 19) and in Fig 2 G segment ST 9 from 2 millimeters and over positive (200 microvolts or over) to be considered as high risk (red light 20) for Acute Myocardial Infarction of the subepicardial type .

As illustrated in Fig 3A a device consists of electrodes 5, 6, 7 and positive and neutral electrodes 11 and 12 entering an instrumentation electrocardiographic amplifier 15 which sends the signals in a voltage range suitable for a Analog to Digital Converter (ADC) 16. By means of the ADC, a microcontroller 17 reads the electrocardiographic data in real time and after processing the information triggers the appropriate alarm green 18 for low risk of Acute Myocardial Infarction (AMI), yellow 19 for medium risk AMI or red 20 and audible tone 21 for high risk of AMI. Batteries 13 are also shown.

As illustrated in Fig 3B, a flow diagram used in the program is contained in a microcontroller unit . The program starts by measuring electrocardiographic data for a short time, 30 seconds, then a unit extracts the ST segment of the electrocardiographic signal and measures its elevation or depression in relation to a baseline . Depending on the result of a ST segment analysis, a electronic analysis unit turns on an alarm if the analysis indicates a possible presence of an Acute Myocardial Infarction. As shown in this Figure, an ST segment deviation above or below the 2 millimeters or 200 microvolts range from the baseline activates the red alarm **20** and audible alarm **21**, a deviation of the ST segment between 1 and 2 millimeters or 100 to 200 microvolts above or below the baseline activates the yellow alarm **19** and no deviation or below or above the baseline 1 millimeter or 100 microvolts of the ST segment activates the green alarm **18**.

OPERATION

With the combination of the five electrodes in the device, four active and one neutral, we are able to obtain the standard electrocardiogram derivations for diagnosing Acute Myocardial Infarction in the different areas of the myocardial muscle, i.e.:

- (a) Inferior Myocardial Infarction with the electrode combination of D II (right armpit 6 and hipogastrium or positive abdomen cable 7), D III (left armpit 5 and hipogastrium or positive abdomen cable 7) and AVF (left armpit 5 and hipogastrium or positive abdomen cable 7)
- (b) Lateral Myocardial Infarction with the electrode combination of AVL (left armpit 5 and hipogastrium or positive abdomen cable 7) and D I (right armpit 6 and left armpit 5)
- (c) Anterior Myocardial Infarction with only one electrocardiographic signal obtained from the precordial lead in V 4 , 11 (intersection of imaginary line of seven to eight intercostal spaces with mid clavicular line).
- (d) Posterior myocardial infarction with the mirror image of anterior leads (precordial electrode 11).

An electronic circuit is placed in the housing and is used by the patient by means of acoustic and light signals to assist in the diagnosis of Acute Myocardial Infarction. A green light means low risk, a yellow light means medium risk, and a red light and an audible alarm means high risk of Acute Myocardial Infarction. Thus, when the patient is under medium or high risk, as alerted by the

device, he/she can seek medical help immediately in order to be administered thrombolysis or any other medical treatment (since we believe that the treatment of Acute Myocardial Infarction should improve dramatically after our CARDIOST becomes available) as fast as possible after the diagnosis.

This should be done in the initial 4 to 6 hours of the myocardial infarction onset, when this treatment is currently being used with an excellent statistically proved outcome in revascularization of the affected infarct zone of the heart. After 6 hours of chest pain the thrombus is well established and thrombolysis is used with a lesser probability of success. As said above, with an improved diagnosis of myocardial ischemia, an early diagnosis, the most important factor of ischemia, will be conducive to the development of more specialized treatments so that thrombolysis will be merely a part of the initial treatment of ischemia, and soon we will have other therapeutic alternatives, possibly influenced by CARDIOST. It is well known that a very large proportion of patients do not seek medical help in the initial hours of Acute Myocardial Infarction, with a subsequent increase in morbidity and mortality, simply because they are not sure about the nature of their chest pain.

We believe that CARDIOST will save many lives in the future, considering that the lack of an early diagnosis of Acute Myocardial Infarction is the leading cause in morbidity and mortality in humans and remains undertreated due to the current lack of procedures for patients to make the right interpretation of their symptoms when pain arises in settings other than a hospital or a doctor's office, which is the case with 99% of the occurrences of Acute Myocardial Infarction. The device is able to diagnose Acute Myocardial Infarction in any of the different areas of the heart which may be in danger, i.e. inferior, lateral, anterior, and posterior, and any combination thereof.

CONCLUSIONS, RAMIFICATIONS, AND SCOPE OF THE INVENTION

Thus the reader will see that diagnosis of Acute Myocardial Infarction may be made by the patient himself when chest pain arises, by connecting the device to his body, thus triggering either acoustic or visual alarms. This will enable him to seek medical help 4-6 hours after symptoms arise, with the advantages of an early thrombolysis or any other treatment available, which will be made possible thanks to an early diagnosis, one of the most difficult problems to be resolved in order to minimize the high morbidity and mortality at present caused by Acute Myocardial Infarction.

Although the above description contains many specificity's, these should not be construed as limiting the scope of the CARDIOST but rather as an exemplification of a preferred embodiment thereof. Many other variations are possible. For example, the device may have other types of alarms, other cable connections, may allow for the analysis of different parts of the electrocardiogram with other diagnosis periods, other treatments proposed , analysis of other waves of the electrocardiogram, etc.

Thus the scope of the CARDIOST should be determined by the appended claims and their legal equivalents, rather than by the examples given.

CLAIMS : We claim:

1. A method for the self-diagnosis by a patient with acute myocardial infarction at the moment of chest pain indicating ischemic activity for
 - a) an early diagnosis in the first four to six hours of said acute myocardial infarction to determine with a high degree of effectiveness when an artery of the heart is acutely obstructed by thrombus or rupture of atherosclerotic plaque related to said ischemic activity
 - b) the immediate use when said patient decides the said chest pain circumstances warrant the diagnosis without having a paramedic or medical doctor or cardiologist available to read the information
 - c) an early diagnosis of said acute myocardial infarction widely known to be poorly interpreted when the said patient himself is in said pain because in acute clinical settings prior to the development of the invention hereunder this has been very difficult to achieve within the said four to six hours because the said patient do not seek medical attention and is a worldwide health problem since said acute myocardial infarction is the leading cause of mortality around the world

d) the use of the device by another person near the said patient with said chest pain since the baseline against which measurement is made is universal in the electronic signal of any electrocardiogram so that said diagnosis can be easily made on any said person which widens the scope of said diagnoses

2. a method for a said patient with said chest pain to be motivated to seek medical advice as soon as possible when there is no definite said diagnosis for said chest pain by means of warnings when the color and audible alarm are displayed as green and the st segment measured against the baseline is between 0-1 millimeters or 100-200 microvolts either positive or negative for subepicardial or subendocardial ischemia there is low risk of ischemic activity when the color and audible alarm are displayed as yellow and the said st segment is between 1-2 millimeters or 100 to 200 microvolts either positive or negative for subepicardial or subendocardial ischemia there is medium risk and when the color and audible alarm are displayed as red color and the said st segment is 2 millimeters or over or 200 microvolts or over either positive or negative for subepicardial or subendocardial ischemia pathology is conclusive and there is high risk of said acute myocardial infarction

a) a method for making the said patient with said chest pain with said ischemic activity

with said acute myocardial infarction seek immediate medical treatment for thrombolysis or any other currently available method influenced by an early said diagnosis

b) a method for modifying the said patient's attitude toward said chest pain by means of a said device that is portable and easy to use by the said patient himself for the purpose of reducing the said high world-wide mortality by said acute myocardial infarction of said ischemic activity


c) a method for the rational use of an immediate said treatment by means of an early said diagnosis that is definitive for the outcome of said acute myocardial infarction through said thrombolysis or any other currently available said treatment.

ABSTRACT


A portable device **(8)** for recognizing Acute Myocardial Infarction by the patient himself without the help of medical doctors or technicians is described. The invention performs a real-time analysis of the ST segment **(9)** in an ambulatory electrocardiographic measurement environment to help the patient decide by himself that he is suffering an Acute Myocardial Infarct.

The device **(8)** is capable of warning the user that he/she may be suffering a heart attack when the ST segment **(9)** is found to be depressed or elevated. The CARDIOST features a simple-to-use portable electrocardiographic amplifier **(15)** and a microcontroller unit **(17)** to analyze the ST segment **(9)** on the signal received from the electrocardiographic amplifier **(15)**. With a software embedded in the microcontroller unit **(17)** the analysis of the ST segment **(9)** delivers the diagnosis to the patient with a visual and acoustic alarm **(18,19,20,21)** representing low, medium or high risk, depending on the status of the ST segment **(9)** shift so that he can seek medical treatment for thrombolysis or any other treatment currently available and influenced by early diagnosis within 4-6 hours without misinterpreting subjective chest pain symptoms, this being a worldwide medical problem since Acute Myocardial Infarction is the leading cause of mortality in the world.

1A




1B




2/8

1C



1D



1. The first part of the paper is devoted to the study of the properties of the function $f(x)$ defined by the equation $f(x) = \sum_{n=0}^{\infty} a_n x^n$, where a_n are the coefficients of the power series.


ST
SEGMENT
NORMAL




The diagram shows a standard ECG trace with the following labels and annotations:

- Q**: The initial downward deflection (S wave).
- R**: The initial upward deflection (R wave).
- S**: The final downward deflection (S wave).
- ST Segment**: The segment between the end of the S wave and the start of the T wave, indicated by a bracket.
- J Point**: The point where the QRS complex meets the ST segment, indicated by a dashed line and a bracket.
- 0-1 mm. (0 - 100 microvolts)**: A scale bar indicating the voltage range for the J point.
- T**: The terminal wave (T wave).
- 9**: A label pointing to the ST segment.
- 10**: A label pointing to the T wave.
- 14**: A label pointing to the J point.
- 22**: A label pointing to the T wave.
- 8**: A label pointing to a box containing a circular pattern of dots, likely representing a heart or a specific electrode.

2C




2D




2E

Green—18




2F

Yellow—19




2G



3A


INTERNAL DIAGRAM



3B

8/8

PROGRAM FLOW DIAGRAM



Declaration for Utility or Design Patent Application

As a below-named inventor, I hereby declare that my residence, post office address, and citizenship are as stated below next to my name and that I believe that I am the original, first, and sole inventor [if only one name is listed below] or an original, first, and joint inventor [if plural names are listed below] of the subject matter which is claimed and for which a patent is sought on the invention, the specification of which is attached hereto and which has the following title:


" Early warning apparatus for Acute Myocardial Infarction "
in the first six hours of pain" (CARDIOST)

I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment specifically referred to in the oath or declaration. I acknowledge a duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, Section 1.56(a).

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Title 18, United States Code, Section 1001, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Please send correspondence and make telephone calls to the First Inventor below.

Signature: Sole/First Inventor: Fernando Anzellini



Print Name: Fernando Anzellini

Date: Sept. 3. 1999

Legal Residence: * Bogota/Colombia

Citizen of: Italy

Post Office Address: Calle 83 No 19-36 (of. 704)

Bogota-Colombia.S.A.

Telephone: 57-1-6160959 or 57-1-6160974

Signature: Joint/Second Inventor: Arturo Sesana



Print Name: Arturo Sesana

Date: Sept 3 1999

Legal Residence: * Bogota-Colombia

Citizen of: Italy

Post Office Address: Calle 100 No 35-67 Ap. 616

Bogota-Colombia.S.A.

Telephone: 57-1-2446605

* City and state, county and state or city, state and country, if foreign

Declaration for Utility or Design Patent Application

As a below-named inventor, I hereby declare that my residence, post office address, and citizenship are as stated below next to my name and that I believe that I am the original, first, and sole inventor [if only one name is listed below] or an original, first, and joint inventor [if plural names are listed below] of the subject matter which is claimed and for which a patent is sought on the invention, the specification of which is attached hereto and which has the following title:

" Early warning apparatus for Acute Myocardial Infarction
in the first six hours of pain" (CARDIOST)

I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment specifically referred to in the oath or declaration. I acknowledge a duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, Section 1.56(a).

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Title 18, United States Code, Section 1001, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Please send correspondence and make telephone calls to the First Inventor below.

Signature: Sole/First Inventor: _____

Print Name: _____ Date: _____

Legal Residence:* _____ Citizen of: _____

Post Office Address: _____

Telephone: _____

Signature: Joint/Second Inventor: Mario G. _____

Print Name: Mario Gongora Date: Sept 3. 1999

Legal Residence:* Bogota-Colombia.S.A. Citizen of: England

Post Office Address: Carrera 13 No 90-55 Ap. 404

Telephone: 57-1-6220453

* City and state, county and state or city, state and country, if foreign.

Please type a plus sign (+) inside this box → ☒

PTO/SB/01 (12-97)

Approved for use through 9/30/00. OMB 0651-0032

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

DECLARATION FOR UTILITY OR DESIGN PATENT APPLICATION (37 CFR 1.63)	Attorney Docket Number	
	First Named Inventor	F. Anzellini
	COMPLETE IF KNOWN	
	Application Number	/
	Filing Date	
	Group Art Unit	
<input checked="" type="checkbox"/> Declaration Submitted with Initial Filing	OR	<input type="checkbox"/> Declaration Submitted after Initial Filing (surcharge (37 CFR 1.16 (e)) required)
Examiner Name		

As a below named inventor, I hereby declare that:

My residence, post office address, and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

Fernando Anzellini/--Arturo Sesana/--
--Mario Gongora

the specification of which **CARDIOST** (Title of the Invention)

☒ is attached hereto
OR
☐ was filed on (MM/DD/YYYY) as United States Application Number or PCT International Application Number and was amended on (MM/DD/YYYY) (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment specifically referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56.

I hereby claim foreign priority benefits under 35 U.S.C. 119(a)-(d) or 365(b) of any foreign application(s) for patent or inventor's certificate, or 365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or of any PCT international application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application Number(s)	Country	Foreign Filing Date (MM/DD/YYYY)	Priority Not Claimed	Certified Copy Attached?	
				YES	NO
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

☐ Additional foreign application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached hereto:

I hereby claim the benefit under 35 U.S.C. 119(e) of any United States provisional application(s) listed below.

Application Number(s)	Filing Date (MM/DD/YYYY)

☐ Additional provisional application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached hereto.

[Page 1 of 2]

Burden Hour Statement: This form is estimated to take 0.4 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☒

PTO/SB/01 (12-97)
Approved for use through 9/30/00. OMB 0651-0032
Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

DECLARATION — Utility or Design Patent Application

I hereby claim the benefit under 35 U.S.C. 120 of any United States application(s), or 365(c) of any PCT international application designating the United States of America, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. 112, I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

U.S. Parent Application or PCT Parent Number	Parent Filing Date (MM/DD/YYYY)	Parent Patent Number (if applicable)

☐ Additional U.S. or PCT international application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached hereto.

As a named inventor, I hereby appoint the following registered practitioner(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

☐ Customer Number → Place Customer Number Bar Code Label here
OR
☐ Registered practitioner(s) name/registration number listed below


Name	Registration Number	Name	Registration Number

☐ Additional registered practitioner(s) named on supplemental Registered Practitioner Information sheet PTO/SB/02C attached hereto.

Direct all correspondence to: ☐ Customer Number OR ☒ Correspondence address below

Name	Fernando Anzellini				
Address	Calle 83 No 19-36(of. 704)				
Address					
City	Bogota	State	---	ZIP	-----
Country	Colombia	Telephone	57-16160959	Fax	57-1-6109091

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Name of Sole or First Inventor:		<input type="checkbox"/> A petition has been filed for this unsigned inventor	
Given Name (first and middle (if any))		Family Name or Surname	
Fernando		Anzellini	
Inventor's Signature			Date Sep/99
Residence: City	Bogota	State	---
		Country	Colombia
		Citizenship	Italian
Post Office Address	Calle 83 No 19-36 (of.704)		
Post Office Address			
City	Bogota	State	----
		ZIP	-----
		Country	Colombia

☐ Additional inventors are being named on the 1 supplemental Additional Inventor(s) sheet(s) PTO/SB/02A attached hereto

Please type a plus sign (+) inside this box → +



PTO/SB/02A (3-97)

Approved for use through 9/30/98. OMB 0651-0032
Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

DECLARATION

ADDITIONAL INVENTOR(S)
Supplemental Sheet
Page 2 of 2

Name of Additional Joint Inventor, if any:		<input type="checkbox"/> A petition has been filed for this unsigned inventor			
Given Name (first and middle [if any])			Family Name or Surname		
Arturo			Sesana		
Inventor's Signature			1999	Sept	
Residence: City	Sta Fe de Bogota	State	Country	Colombia	Citizenship
Post Office Address					
Calle 100 No 35-67 Ap 616					
Post Office Address					
City	Sta Fe de Bogota	State	ZIP	Country	Colombia
Name of Additional Joint Inventor, if any:		<input type="checkbox"/> A petition has been filed for this unsigned inventor			
Given Name (first and middle [if any])			Family Name or Surname		
Mario			Gongora		
Inventor's Signature			1999	Sept	
Residence: City	Sta Fe de Bogota	State	Country	Colombia	Citizenship
Post Office Address					
Carrera 13 No 90-55 Ap. 404					
Post Office Address					
City	Sta Fe de Bogota	State	ZIP	Country	Colombia
Name of Additional Joint Inventor, if any:		<input type="checkbox"/> A petition has been filed for this unsigned inventor			
Given Name (first and middle [if any])			Family Name or Surname		
Inventor's Signature			Date		
Residence: City		State	Country		Citizenship
Post Office Address					
Post Office Address					
City		State	ZIP	Country	

Burden Hour Statement: This form is estimated to take 0.4 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.